Go Pro
NASDAQ:QTRX

Quanterix Q3 2024 Earnings Report

Quanterix logo
$3.16 -0.03 (-0.94%)
Closing price 09/23/2026 04:00 PM Eastern
Extended Trading
$3.16 +0.00 (+0.16%)
As of 09/23/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Quanterix EPS Results

Actual EPS
-$0.22
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Quanterix Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Quanterix Announcement Details

Quarter
Q3 2024
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Quanterix's Q3 2026 earnings is estimated for Monday, November 9, 2026, based on past reporting schedules, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Quanterix Earnings Headlines

Analyzing Quanterix (NASDAQ:QTRX) & OmniAb (NASDAQ:OABI)
Quanterix (NASDAQ:QTRX) Raised to "Hold" at Wall Street Zen
Why I went to Mount Rushmore
A small miner just hit on gold in the hills surrounding Mount Rushmore, thanks to a breakthrough new technology. This could be one of the biggest gold finds since the 1870s, yet the stock still trades around 6 dollars. BlackRock and Vanguard have been quietly loading up on shares while most investors have missed the story. The same technology is unlocking hidden resource wealth across America, driving stocks up 227 percent, 378 percent, and even 773 percent.tc pixel
Quanterix Names Yuri Fesko Chief Medical Officer
See More Quanterix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Quanterix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Quanterix and other key companies, straight to your email.

About Quanterix

Quanterix (NASDAQ:QTRX) (NASDAQ:QTRX) is a life sciences company that develops ultra-sensitive digital immunoassay technologies for detecting and measuring biomarkers in blood and other biological samples. Its platform is designed to identify proteins and other biomarkers at concentrations significantly below the capabilities of many conventional immunoassay methods, supporting research into disease biology, diagnosis, treatment development and monitoring.

The company’s primary technology, Simoa, is used in its laboratory instruments, assay kits, consumables and software products. Quanterix offers systems such as the HD-X, SR-X and SP-X platforms, along with assays for applications that include neurology, oncology, immunology, cardiology and infectious disease research. It also provides laboratory services and access to its technology for pharmaceutical, biotechnology, academic and clinical research organizations.

Quanterix was founded in 2007 by David Walt, a scientist and professor associated with Harvard University and the Wyss Institute. The company serves customers internationally through direct operations, commercial partners and distributors. Its corporate headquarters are in Billerica, Massachusetts, and Masoud Toloue serves as president and chief executive officer.

View Quanterix Profile